| Siga Pharmaceuticals, Inc. | |||
| Ticker: | SGPH | 666 Third Avenue | |
| Exchange: | NASDAQ-Small Cap Market | New York, NY 10017 | |
| Industry: | Manufacturing (SIC Code 2834) | (212) 681-4970 | |
| Type of Shares: | Common Shares | Filing Date: | 3/10/97 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 9/8/97 | |
| Non-U.S. Shares: | 0 | Filing Price: | $5.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $5.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.46 | |
| Offering Amount: | $12,500,000 | Selling: | $0.25 | |
| Expenses: | $280,000 | Reallowance: | ||
| Shares Out After: | 6,617,182 |
| Manager | Tier | Phone |
| Sunrise Securities Corp. | Lead Manager | (212) 421-1616 |
| M.H. Meyerson & Company | Co-manager | (201) 459-9448 |
| Issuer's Law Firm: | Eilenberg & Zivian |
| Bank's Law Firm: | Squadron, Ellenoff, Plesent, Sheinfeld & Sorkin |
| Auditor: | Price Waterhouse |
| Registrar/Transfer Agent: | American Stock Transfer & Trust Co |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/96 | 12/31/96 | ||||
| Revenue: | $0.00 | Assets: | $0.58 | ||
| Net Income: | -$2.27 | Curr Assets: | |||
| EPS: | -$0.66 | Liabilities: | $0.18 | ||
| Prior EPS: | Curr Liabilities: | ||||
| Cash Flow/Oper: | -$2.12 | Equity: | $0.40 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company is a development stage, biopharmaceutical company focused on the discovery, development and commercialization of vaccines, antibiotics and novel anti-infectives for serious infectious diseases. The company's lead vaccine candidate is for the prevention of "strep throat." The company is developing a technology for the mucosal delivery of its vaccines which may allow those vaccines to activate the immune system at the mucus-lined surfaces of the body - the mouth, the nose, the lungs and the gastrointestinal and urogenital tracts - the sites of entry for most infectious agents. The company's anti-infectives programs, aimed at the increasingly serious problem of drug resistance, are designed to block the ability of bacteria to attach to human tissue, the first step in the infection process. The company's technologies are licensed from The Rockefeller University. The company is collaborating with the National Institutes of Health and the University of Maryland Center for Vaccine Development on the clinical development of this vaccine candidate and expects to file and Investigational New Drug Application with the United States FDA in 1997. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to repay short term indebtedness, fund research and development activities, working capital and general corporate purposes. |